Ascendis Pharma/ASND

$121.96

0.74%
-
1D1W1MYTD1YMAX

About Ascendis Pharma

Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).

Ticker

ASND

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Jan Moller Mikkelsen

Employees

879

Headquarters

Hellerup, Denmark

Ascendis Pharma Metrics

BasicAdvanced
$7.1B
Market cap
-
P/E ratio
-$9.66
EPS
0.56
Beta
-
Dividend rate
$7.1B
0.56394
$161.00
$83.75
350K
0.831
0.54
-2.73%
-56.71%
-130.03%
19.718
322.18%
12.65%
237.26%

What the Analysts think about Ascendis Pharma

Analyst Ratings

Majority rating from 14 analysts.
Buy

Price Targets

Average projection from 12 analysts.
48.65% upside
High $261.23
Low $139.59
$121.96
Current price
$181.29
Average price target

Ascendis Pharma Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-136.74% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
€96M
-30.43%
Net income
-€131M
50.92%
Profit margin
-136.74%
116.94%

Ascendis Pharma Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 53.09%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-€2.16
-€2.88
-€1.54
-€2.30
-
Expected
-€2.59
-€2.38
-€2.03
-€1.50
-€1.37
Surprise
-16.62%
21.08%
-24.02%
53.09%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
ADR

Upcoming events

FAQs

What’s the current market cap for Ascendis Pharma stock?

Ascendis Pharma (ASND) has a market cap of $7.1B as of May 22, 2024.

What is the P/E ratio for Ascendis Pharma stock?

The price to earnings (P/E) ratio for Ascendis Pharma (ASND) stock is 0 as of May 22, 2024.

Does Ascendis Pharma stock pay dividends?

No, Ascendis Pharma (ASND) stock does not pay dividends to its shareholders as of May 22, 2024.

When is the next Ascendis Pharma dividend payment date?

Ascendis Pharma (ASND) stock does not pay dividends to its shareholders.

What is the beta indicator for Ascendis Pharma?

Ascendis Pharma (ASND) has a beta rating of 0.56. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Ascendis Pharma stock price target?

The target price for Ascendis Pharma (ASND) stock is $181.41, which is 47.67% above the current price of $122.85. This is an average based on projections from 12 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Ascendis Pharma stock

Buy or sell Ascendis Pharma stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing